4.1 Article

Discovery of 2-phenoxyacetamides as inhibitors of the Wnt-depalmitoleating enzyme NOTUM from an X-ray fragment screen

Journal

MEDCHEMCOMM
Volume 10, Issue 8, Pages 1361-1369

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/c9md00096h

Keywords

-

Funding

  1. Cancer Research UK [C375/A17721, FC001002]
  2. Wellcome Trust [102 164/B/13/Z, FC001002).]
  3. Wellcome Trust funds the Wellcome Centre for Human Genetics, University of Oxford [203 141/Z/16/Z]
  4. Alzheimer's Research UK (ARUK)
  5. Francis Crick Institute
  6. Alzheimer's Research UK [520909]
  7. UK Medical Research Council [FC001002]
  8. EPSRC [EP/K005030/1, EP/P020410/1] Funding Source: UKRI

Ask authors/readers for more resources

NOTUM is a carboxylesterase that has been shown to act by mediating the O-depalmitoleoylation of Wnt proteins resulting in suppression of Wnt signaling. Here, we describe the development of NOTUM inhibitors that restore Wnt signaling for use in in vitro disease models where NOTUM over activity is an underlying cause. A crystallographic fragment screen with NOTUM identified 2-phenoxyacetamide 3 as binding in the palmitoleate pocket with modest inhibition activity (IC50 33 mu M). Optimization of hit 3 by SAR studies guided by SBDD identified indazole 38 (IC50 0.032 mu M) and isoquinoline 45 (IC50 0.085 mu M) as potent inhibitors of NOTUM. The binding of 45 to NOTUM was rationalized through an X-ray co-crystal structure determination which showed a flipped binding orientation compared to 3. However, it was not possible to combine NOTUM inhibition activity with metabolic stability as the majority of the compounds tested were rapidly metabolized in an NADPH-independent manner.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available